tbuckley/cabot-search huggingface dataset:
Impact of treatment with bilastine for PD-1/PD-L1 inhibitors induced rash
Authors: T. Hirata
Journal: Annals of Oncology (2019)

Background: PD-1/PD-L1 inhibitors are novel anti-cancer agents for various tumors. PD-1/PD-L1 inhibitors induced rash occurred in 20% to 30%. The therapy for rash includes anti-histamine and corticosteroid. Bilastine is a non-sedating second-generation H1-antihistamine. Bilastine showed the efficacy for urticaria, prurigo and cutaneous pruritus. However, its effectiveness for PD-1/PD-L1 inhibitors induced rash is unknown. The objective of this retrospective study was to evaluate the efficacy of bilastine for PD-1/PD-L1 inhibitors induced rash. Methods: We identified 224 patients who received PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, atezolizumab) at the Kure Medical Center from September 2014 to October 2018. PD-1/PD-L1 inhibitors induced rashes were observed in 84 patients (37.5%). They were classified into 4 groups on the basis of the systemic antihistamine and topical corticosteroid therapy: the (1) bilastine and corticosteroid group (n = 18), (2) another anti-histamine and corticosteroid group (n = 22), (3) bilastine group (n = 20); and (4) another antihistamine group (n = 24). Adverse events were graded according to the Common Terminology Criteria for Adverse Events (version 4.0). This study was approved by the Kure Medical Center IRB. Results: The bilastine and corticoegsteroid group had significantly shorter the median duration of topical corticosteroids and antihistamine than the another antihistamine and corticosteroid group (p<0.01). Bilastine group had significantly shorter the period of systemic medications than the another antihistamine group (p<0.01). The incidence of adverse events was observed as follows, somnolence in 3% (1/38), headache 3% (1/38) and dizziness in 3% (1/38) in the bilastine and corticosteroid group and bilastine group. There were no serious adverse events. Conclusions: Bilastine treatment reduced the need for topical corticosteroids use and shortened the period of topical corticosteroids for PD-1/PD-L1 inhibitors induced rash with acceptable safety profiles. Bilastine may be more effective than another antihistamine for PD-1/PD-L1 inhibitors induced rash. Legal entity responsible for the study: Taizo Hirata. Funding: Has not received any funding. Disclosure: The author has declared no conflicts of interest.
Cancer treatment and survivorship statistics, 2016
Authors: Kimberly D. Miller, Rebecca L. Siegel, Chun Chieh Lin, Angela B. Mariotto, Joan L. Kramer, Julia H. Rowland, Kevin D. Stein, Rick Alteri, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2016)

The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population. For the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results cancer registries. In addition, current treatment patterns for the most prevalent cancer types are presented based on information in the National Cancer Data Base and treatment-related side effects are briefly described. More than 15.5 million Americans with a history of cancer were alive on January 1, 2016, and this number is projected to reach more than 20 million by January 1, 2026. The 3 most prevalent cancers are prostate (3,306,760), colon and rectum (724,690), and melanoma (614,460) among males and breast (3,560,570), uterine corpus (757,190), and colon and rectum (727,350) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost one-half (47%) are aged 70 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by primary care providers. Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care. CA Cancer J Clin 2016;66:271-289. © 2016 American Cancer Society.
Theranostic Nanodots with Aggregation-Induced Emission Characteristic for Targeted and Image-Guided Photodynamic Therapy of Hepatocellular Carcinoma
Authors: Yang Gao, Qi Chang Zheng, Shidang Xu, Youyong Yuan, Xiang Cheng, Shuai Jiang,  Kenry, Qihong Yu, Zifang Song, Bin Liu, Min Li
Journal: Theranostics (2019)

Photosensitizer (PS) serves as the central element of photodynamic therapy (PDT). The use of common nanoparticles (NPs) for PDT has typically been rendered less effective by the undesirable aggregation-caused quenching (ACQ) effect, resulting in quenched fluorescence and reduced reactive oxygen species (ROS) generation that diminish the imaging quality and PDT efficacy. To overcome the ACQ effect and to enhance the overall efficacy of PDT, herein, integrin ανβ3-targeted organic nanodots for image-guided PDT were designed and synthesized based on a red emissive aggregation-induced emission (AIE) PS. Methods: The TPETS nanodots were prepared by nano-precipitation method and further conjugated with thiolated cRGD (cRGD-SH) through a click reaction to yield the targeted TPETS nanodots (T-TPETS nanodots). Nanodots were characterized for encapsulation efficiency, conjugation rate, particle size, absorption and emission spectra and ROS production. The targeted fluorescence imaging and antitumor efficacy of T-TPETS nanodot were evaluated both in vitro and in vivo. The mechanism of cell apoptosis induced by T-TPETS nanodot mediated-PDT was explored. The biocompatibility and toxicity of the nanodots was examined using cytotoxicity test, hemolysis assay, blood biochemistry test and histological staining. Results: The obtained nanodots show bright red fluorescence and highly effective 1O2 generation in aggregate state. Both in vitro and in vivo experiments demonstrate that the nanodots exhibit excellent tumor-targeted imaging performance, which facilitates image-guided PDT for tumor ablation in a hepatocellular carcinoma model. Detailed analysis reveals that the nanodot-mediated PDT is able to induce time- and concentration-dependent cell death. The use of PDT at a high PDT intensity leads to direct cell necrosis, while cell apoptosis via the mitochondria-mediated pathway is achieved under low PDT intensity. Conclusion: Our results suggest that well-designed AIE nanodots are promising for image-guided PDT applications.
Tuberculosis case detection by trained inmate peer educators in a resource-limited prison setting in Ethiopia: a cluster-randomised trial
Authors: Kelemework Adane, Mark Spigt, Bjorn Winkens, Geert-Jan Dinant
Journal: The Lancet Global Health (2019)

To improve tuberculosis case detection, interventions that are feasible with available resources are needed. We investigated whether involving trained prison inmates in a tuberculosis control programme improved tuberculosis case detection, shortened pre-treatment symptom duration, and increased treatment success in a resource-limited prison setting in Ethiopia.In this cluster-randomised trial we randomly assigned prisons in the regions Amhara and Tigray of Ethiopia to an intervention group or a control group, after matching them into pairs based on their geographical proximity and size. Larger prisons were considered eligible whereas smaller prisons were excluded. We selected three to six prison inmates in each intervention prison. The recruited prison inmates who received a 3-day training course and were capable of identifying presumptive tuberculosis cases then provided health education to all other prison inmates about tuberculosis prevention and control every 2 weeks for 1 year. They also actively searched for symptomatic prison inmates and undertook routine symptom-based tuberculosis screening. The control prisons followed the existing passive case finding system. The primary outcome was the mean case detection rate at the end of the year, measured at cluster (prison) level. This trial is registered at ClinicalTrials.gov, number NCT02744521.We randomly assigned 16 prisons with a total population of 18 032 inmates to either the intervention group (n=8) or the control group (n=8) from April 1, 2016, to March 31, 2017. During the 1-year study period, 75 new tuberculosis cases (1% of 8874 total inmates) were detected in the intervention prisons and 25 new cases (<1% of 9158 total inmates) were detected in the control prisons. The mean case detection rate was significantly higher in the intervention group than in the control group (mean difference 52·9 percentage points, 95% CI 17·5-88·3, p=0·010).Involving trained inmate peer educators in the tuberculosis control programme in Ethiopian prisons significantly improved the tuberculosis case detection rate. The findings have important implications for clinical and public health policy, particularly in prisons of low-income countries where tuberculosis burden is high and the recommended tuberculosis diagnostic and treatment algorithms have generally not been implemented.Nuffic, Mekelle University.
Abstract 286: Feasibility Study for Performing Effective Chest Compressions According to the American Heart Association 2010 Guidelines for CPR and ECC
Authors: Yoshitaka Shimizu, Koichi Tanigawa, Masami Ishikawa, Masahiro Irifune
Journal: Circulation (2012)

Background: The American Heart Association 2010 Guidelines for CPR recommend that untrained bystanders provide CPR using chest compression only with an emphasis on “push hard and fast” (a chest compression depth of &gt;5cm at a rate of &gt;100 compressions/minute). This study aimed to determine the feasibility of performing effective chest compressions according to the 2010 guidelines in comparison with the 2005 guidelines. Methods: Fifty-eight sixth-year dentistry students participated in this study. They were divided into 2 groups, g-G2010 and g-G2005. The students were instructed to perform chest compressions according to the 2010 guidelines (g-G2010; compression rate &gt;100 times per minute and &gt;5 cm depth), or the 2005 guidelines (g-G2005; compression rate=100 times per minute and a depth of 4 to 5 cm). Both groups were asked to compress the chest of a manikin (HeartSim 4000, Laerdal Co.) for 5 one-minute sets, with a ten-second break between each set. Results: The average numbers of chest compressions were 114 and 105 per minute in g-G2010 and g-G2005, respectively. Both groups maintained compression rates greater than 100 per minute during the 5-minute study period. In g-G2010, chest compressions deeper than 5 cm were achieved only in 58 ± 10 compressions in the first set, and this number decreased to 50 ± 10* compressions in the second set (*p&lt;0.01 vs. the first set). The number of compressions deeper than 4 cm decreased significantly from 108 ± 4 in the first set to 97 ± 7* per minute in the second set (* p&lt;0.05 vs. the first set). In g-G2005, on the other hand, the number of compressions deeper than 4 cm was 97 ± 5 in the first set, and decreased to 92 ± 6 in the second set (n.s.). In the third set, the number of compressions deeper than 4 cm in g-2010 further decreased to 84 ± 7* per minute, which was significantly lower than g-2005, which was 91 ± 6 in the same time set (*p&lt;0.05 vs. g-2005). Conclusions: Our study demonstrated that the compression depth in g-G2010 was inadequate in half of the compressions during the first minute of CPR, and its quality degraded further thereafter. These results suggest that the recommended depth of compression in the 2010 guidelines might be difficult for lay rescuers to achieve in compression-only CPR.
Arthroscopic Partial Meniscectomy vs Physical Therapy for Nonobstructive Meniscal Tears—Reply
Authors: Victor A. van de Graaf, Nienke W. Willigenburg, Rudolf W. Poolman
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Progress Toward Global Eradication of Dracunculiasis —January 2015–June 2016
Authors: Donald R. Hopkins, Ernesto Ruiz-Tiben, Mark L. Eberhard, Sharon L. Roy, Adam J. Weiss
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Dracunculiasis (Guinea worm disease) is caused by Dracunculus medinensis, a parasitic worm. Approximately 1 year after a person acquires infection from drinking contaminated water, the worm emerges through the skin, usually on the leg. Pain and secondary bacterial infection can cause temporary or permanent disability that disrupts work and schooling. The campaign to eradicate dracunculiasis worldwide began in 1980 at CDC. In 1986, the World Health Assembly called for dracunculiasis elimination (1), and the global Guinea Worm Eradication Program, led by the Carter Center and supported by the World Health Organization (WHO), United Nations Children's Fund (UNICEF), CDC, and other partners, began assisting ministries of health in countries where dracunculiasis was endemic. In 1986, an estimated 3.5 million cases were occurring each year in 20 countries in Africa and Asia (1,2). Since then, although the goal of eradicating dracunculiasis has not been achieved, substantial progress has been made. Compared with the 1986 estimate, the annual number of reported cases in 2015 has been reduced by >99%, and cases are confined to four countries with endemic disease. This report updates published (3-5) and unpublished surveillance data reported by ministries of health and describes progress toward dracunculiasis eradication during January 2015-June 2016. In 2015, a total of 22 cases were reported from four countries (Chad [nine cases], Mali [five], South Sudan [five], and Ethiopia [three]), compared with 126 cases reported in 2014 from the same four countries (Table 1). The overall 83% reduction in cases from 2014 to 2015 is the largest such annual overall reduction ever achieved during this global campaign. During the first 6 months of 2016, however, cases increased 25% compared with the same period in 2015. Continued active surveillance and aggressive detection and appropriate management of cases are essential eradication program components; however, epidemiologic challenges and civil unrest and insecurity pose potential barriers to eradication.
Thyroid Hormone Therapy for Subclinical Hypothyroidism
Authors: Salman Razvi, Robin Peeters, Simon H. S. Pearce
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IMMU-45. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY
Authors: Johanna Theruvath, Sabine Heitzeneder, Robbie Majzner, Karen Cui, Anandani Nellan, Claus Moritz Graef, Samuel H Cheshier, Crystal Mackall, Siddhartha S Mitra
Journal: Neuro-Oncology (2017)

B7-H3 (CD276) is a member of the B7 family of molecules involved in immune regulation and is over-expressed on a wide variety of solid tumor types. The Mackall group previously created a second-generation chimeric antigen receptor (CAR) T-cell targeting B7-H3 with the 4-1BB using a binder based on antibody MGA271, which showed strong efficacy against an osteosarcoma model. The goal of this study was to test the anti-tumor function of the B7-H3 CAR in a myc-amplified highly aggressive medulloblastoma xenograft model. We screened several medulloblastoma cell lines for B7-H3 expression and tested cytokine release (IL-2, TNF-α, INF-g) in vitro. Immunodeficient mouse xenograft models of a human Group 3, myc-amplified medulloblastoma cancer cell-line (D425) was used for in vivo efficacy studies. High expression of B7-H3 antigen was observed on various medulloblastoma cell lines (D425, MED8A, SU_MB002, D283, D341) and a freshly resected primary tumor sample classified as group 2 SHH subgroup. 24hr co-incubation of B7-H3 CAR T-cells and tumor cells resulted in a high cytokine release of IL-2, TNF-α, INF-g. Administration of a single intratumoral infusion of 1 x 106 B7-H3 CAR T-cells into the posterior fossa was able to eradicate tumor burden. Furthermore, intravenous administered single infusion of 10x 106 B7-H3 CAR T-cells succeeded in crossing the blood-brain barrier and lead to prolonged survival (p= 0,007). We show B7-H3 overexpression on various medulloblastoma and primary patient sample. CAR T-cell targeting B7-H3 is efficacious in eradicating medulloblastoma.
Angiopoietin‐2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma
Authors: Paola Todesca, Luca Marzi, Rosina Maria Critelli, Biagio Cuffari, Cristian Caporali, Laura Turco, Giovanni Pinelli, Filippo Schepis, Lucia Carulli, Nicola de Maria, Federico Casari, Riccardo Scaglioni, Erica Villa
Journal: Hepatology (2019)

Todesca, Paola; Marzi, Luca; Critelli, Rosina Maria; Cuffari, Biagio; Caporali, Cristian; Turco, Laura; Pinelli, Giovanni; Schepis, Filippo; Carulli, Lucia; de Maria, Nicola; Casari, Federico; Scaglioni, Riccardo; Villa, Erica Author Information
Treatment Burden in Patients with Multiple Myeloma According to Comorbidity
Authors: Ernesto Pérez Persona, Ariane Unamunzaga Cilaurren, Ana Vega Gonzalez de Viñaspre, Itziar Oiartzabal Ormategui, Ana Santamaría Lopez, Laida Cuevas Palomares, Diego Robles de Castro, Carlos de Miguel Sanchez, Miren Gabilondo Jalón, Angel Pereda Vicandi, Arantza Mendizábal, Jose María Guinea de Castro
Journal: Blood (2018)
Graphic Medicine: The Best of 2018
Authors: Michael J. Green, Mita Mahato
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
(9) Cutis marmorata telangiectatica congenita
Authors: S.B. Bittiner, R.E. Church
Journal: British Journal of Dermatology (1986)

Journal Article (9) Cutis marmorata telangiectatica congenita Get access S.B. Bittiner, Drs, S.B. Bittiner, Drs Search for other works by this author on: Oxford Academic Google Scholar R.E. Church R.E. Church Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 115, Issue s30, 1 July 1986, Page 51, https://doi.org/10.1111/j.1365-2133.1986.tb07704.x Published: 01 July 1986
Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation
Authors: Yujiao Han, Heng Feng, Jun Sun, Xiaoting Liang, Zhuo Wang, Wenhui Xing, Qinggang Dai, Yang Yang, Anjia Han, Zhanying Wei, Qing Bi, Hongbin Ji, Tiebang Kang, Weiguo Zou
Journal: Journal of Clinical Investigation (2019)

Bone osteogenic sarcoma has a poor prognosis as the exact cell of origin and the signaling pathways underling tumor formation remain undefined. Here, we report an osteogenic tumor mouse model based on the conditional knockout of liver kinase b1 (Lkb1; also known as Stk11) in Cathepsin K (Ctsk)-Cre expressing cells. Lineage tracing studies demonstrated that Ctsk-Cre could label a population of periosteal cells. The cells functioned as mesenchymal progenitors with regard to markers and functional properties. LKB1 deficiency increased proliferation and osteoblast differentiation of Ctsk+ periosteal cells, while downregulation of mTORC1 activity, using Raptor genetic mouse model or mTORC1 inhibitor treatment, ameliorated tumor progression of Ctsk-Cre Lkb1fllfl mice. Xenograft mouse models, using human osteosarcoma cell lines, also demonstrated that LKB1 deficiency promoted tumor formation, while mTOR inhibition suppressed xenograft tumor growth. In summary, we identified periosteum-derived Ctsk-Cre expressing cells as a cell of origin for osteogenic tumor and suggested the LKB1-mTORC1 pathway as a promising target for treatment of osteogenic tumor.